WO2012108748A2 - Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait d'albizzia julibrissin - Google Patents

Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait d'albizzia julibrissin Download PDF

Info

Publication number
WO2012108748A2
WO2012108748A2 PCT/KR2012/001082 KR2012001082W WO2012108748A2 WO 2012108748 A2 WO2012108748 A2 WO 2012108748A2 KR 2012001082 W KR2012001082 W KR 2012001082W WO 2012108748 A2 WO2012108748 A2 WO 2012108748A2
Authority
WO
WIPO (PCT)
Prior art keywords
brain cancer
composition
extract
brain
cancer
Prior art date
Application number
PCT/KR2012/001082
Other languages
English (en)
Korean (ko)
Other versions
WO2012108748A3 (fr
Inventor
황성연
정경채
Original Assignee
주식회사 한국전통의학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 한국전통의학연구소 filed Critical 주식회사 한국전통의학연구소
Publication of WO2012108748A2 publication Critical patent/WO2012108748A2/fr
Publication of WO2012108748A3 publication Critical patent/WO2012108748A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Definitions

  • the present invention relates to a novel use of haphwanpi extract.
  • the present invention relates to a therapeutic composition and cosmetic composition containing a haphwanpi extract as an active ingredient exhibiting excellent prophylactic or therapeutic efficacy against brain cancer.
  • Brain cancer refers to abnormally increased proliferation of any type of neuron, also referred to as primary brain cancer, or any other cancer that metastasizes to the central nervous system (CNS), also referred to as brain metastasis.
  • CNS central nervous system
  • Primary brain cancer can only occur in those cases where the nerve cells lose their protective ability to undergo apoptosis.
  • Examples of primary brain cancers include, but are not limited to, neuroma, astrocytoma, neuroblastoma, glioma, meningioma, oligodendrocyte, stromal blastoma, spinal cord tumor and neuromyoma.
  • Gliomas comprise about 60% of all primary CNS tumors and typically occur in the cerebral hemispheres of the brain, but can be found in other areas such as the visual nerve, brain stem or cerebellum. Gliomas can be classified into groups according to the type of glial cell from which they originated (Kornblith et al, (1986), Cancer: Principles and Practice of Oncology, 2nd Ed., DeVita, V., Hellman, S., Rosenberg , S, eds., JB Lippincott Company, Philadelphia, Chapter 41: Neoplasms of the Central Nervous System). The most common type of glioma is astrocytoma. These tumors develop from star-shaped glial cells called astroglia.
  • Astrocytes are assigned a rating according to their malignancy.
  • Low-grade astrocytomas also known as grade I and II astrocytomas
  • Mid-grade astrocytoma also known as grade III astrocytoma
  • Grade III astrocytoma is treated with radiation and some chemotherapy following surgery.
  • High-grade astrocytoma also known as grade IV astrocytoma
  • Grade IV astrocytomas are usually treated with a combination of radiation and chemotherapy following surgery.
  • Glioblastoma multiforme is a grade IV astrocytoma, which is the most malignant and lethal primary brain tumor (Id).
  • Id primary brain tumor
  • the benefit of treatment is minimal, and treatment can significantly reduce the quality of the patient's short-lived life.
  • CNS tumors represent the most common group of solid tumors in young patients, there is a clear need in the art for primary brain cancer prevention and treatment methods that overcome the disadvantages of the above-mentioned conventional approaches.
  • Brain tumors are a secondary-induced cause of cancer-related death in infants, with approximately 25% of all such deaths, with current therapies in which most of these infants die within the first year of diagnosis.
  • Brain metastasis results from primary tumors elsewhere in the body, including, but not limited to, lung cancer (both small and non-small cell), breast cancer, colorectal cancer, prostate cancer, melanoma and pancreatic cancer. Particularly in patients with metastatic breast cancer, the incidence of brain metastasis is diagnosed at a rate of 10-20% (Tyson, R.M. et al, Therapy 3 (1), 97-112 (2006)).
  • Breast cancer is the second leading cause of cancer-related death in women, and nearly all deaths from breast cancer are due to metastatic disease with brain metastases found in 30% of patients at autopsy.
  • Standard modes of treatment include surgical resection, chemotherapy and radiation therapy, in particular whole-brain radiation therapy (WBRT) and stereotactic radiosurgery or combinations thereof.
  • Surgery for brain metastases can improve survival, especially in patients with a single lesion. Surgery, however, may not be possible in terms of multiple lesions, lesions that are difficult to surgically approach, or inability to withstand surgery. In breast cancer, 50% of patients with brain cancer metastases have multiple metastases, making them less suitable as surgical candidates.
  • WBRT can improve intermediate survival over untreated and as an adjuvant for surgery, which reduces the chance of relapse and dying nerve death, but does not change survival or level of action.
  • SRS provides a method for treating brain metastases that cannot be surgically resected by location or patient symptoms.
  • SRS provides an improvement in quality of life but does not provide survival benefits, except for patients with a single metastasis.
  • the use of chemotherapy in the treatment of brain metastases is hampered by the impossibility of high molecular weight compounds, limiting most chemotherapeutic agents across the blood brain barrier. This is reflected in the fact that chemosensitive tumors, such as most metastatic breast carcinomas, often exhibit a complete systemic response to chemotherapy simultaneously with tumor progression in the brain.
  • this initial resistance to the use of chemotherapy in the treatment of brain metastases has recently changed based on observations in animal models and human brain tumor autopsies, and metastatic lesions cause blood brain barrier insufficiency, whereby chemotherapy Drugs can always enter the tumor.
  • Radiation therapy combined with chemotherapy has evolved from a first-line approach in the treatment of brain metastases.
  • Some problems associated with the above approaches include (i) deleterious side effects, including alteration of intelligence, learning ability, memory, motor skills, consciousness and emotions; (ii) recurrence of tumors within 3 to 5 years of treatment because of the development of resistance to these therapies; (iii) death due to ineffectiveness of this treatment. From the foregoing, it will be apparent that there is an urgent need to develop a chemotherapeutic agent that can cross the blood brain barrier in an effective amount to reduce neoplastic expansion and / or growth of cancer in the central nervous system, which is not yet satisfied.
  • Brain cancer is a generic term for primary brain cancer that develops in the brain tissue and the envelope that surrounds the brain, and secondary brain cancer that has metastasized from cancer that occurs in the skull or other parts of the body.
  • Such brain cancers are often distinguished from cancers occurring in other organs.
  • lung, stomach, and breast cancers occur in one or two types of organs, and their properties are the same and similar.
  • the brain develops a wide variety of cancers. For example, glioblastoma multiforme, malignant gliomas, lymphomas, germ cell tumors, metastatic tumors, and the like.
  • glioma especially glioblastoma multiforme (GBM)
  • GBM glioblastoma multiforme
  • Albizzie Cortex ( Albizzia julibrissin ) is a bark of the Azalea , a legume.
  • Azaleas are deciduous trees, 10 m high, trunk black and gray, and the hairs are hairless and ridged.
  • the leaves are shifted to the right upper bilobal, 5 to 15 pairs in the right side, the lobules are sickle oblong, the tip of the leaf is small and pointed, the leaf bottom is not symmetrical, the leading edge and the lanceolate is linear lanceolate.
  • the flower runs from the end of the branch to the head inflorescence, and the entire peduncle has hairs.
  • the fruit is flat as a legume.
  • Albizziae Cortex is a herb listed in the Korean Pharmacopoeia Standards, and the bark of Albizziae CortexD aurazzinii is widely used as a favorite food, drink and functional food in the private sector.
  • Haphwanpi harmonizes the heart and spleen
  • oriental medicine is used for mental anxiety, forgetfulness, insomnia, depression, and mood swings, and it is known to stabilize bones and fractures and to harmonize the wick so as not to be depressed (Shinnonboncho, p83, 1982).
  • Hwanhwan Blood is used to treat tumors and to treat fractures and muscle injuries caused by bruises, because Hwanhwan Blood protects the heart and spleen. (Completed Chinese Medicine Dictionary, p6017 ⁇ 9, 1998) ).
  • it is used for Haul, Hwahwa, Spirit, Soongjong, etc.
  • Hwanhwanpi extract can be effectively used for the prevention and improvement of various diseases in which it inhibits the activity of matrix metalloproteinases involved in numerous physiological processes such as embryonic development, tissue formation, salivary gland formation, and embryonic development. .
  • it is safe for the human body as a plant extract, so there are almost no side effects even when used for a long time.
  • the present inventors completed the present invention by confirming that the extract of the hwanhwanpi can effectively kill brain cancer cells during the herbal research on the haphwanpi.
  • the present invention provides a composition for the prevention and treatment of brain cancer, including the active ingredient extracted from haphwanpi with an organic solvent.
  • the organic solvent is preferably ethanol.
  • the present invention provides a cosmetic composition for preventing brain cancer containing a synthetic ring ethanol extract containing an acceptable additive as an active ingredient.
  • the present invention provides a composition for the prevention and treatment of brain cancer containing Albizziae Cortex ethanol extract as an active ingredient.
  • the ethanol extract is preferably extracted for 24 hours at 50 °C, wherein the ethanol extract is more preferably dried and concentrated at 45 °C reduced pressure conditions, the ethanol is Most preferred is 95%.
  • the composition for the prevention and treatment of brain cancer of the present invention is selected from the primary brain cancer crowd consisting of neuroma, astrocytoma, neuroblastoma, glioma, meningioma, rare oligodendrocyte, stromal blastoma, spinal cord tumor and neuromyoma It is preferably applied to brain cancer.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • composition for treating brain cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • Formulations for the formulation of the haphwanpi extract of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants And diluents such as surfactants or excipients.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as injectable water. Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • the ethanol extract of Hwanhwan bark killed 89.5% of U-87 MG brain cancer cells at 100 ⁇ g / ml, and the EC 50 (half maximal effective concentration) was 39.831 ⁇ g / ml.
  • the above results demonstrate that the Hwanhwanpi extract of the present invention has excellent killing activity of U-87 MG brain cancer cells and further has brain cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the onset of brain cancer by administration of the composition.
  • treatment means any action that improves or advantageously alters the symptoms of brain cancer by administration of the composition.
  • Hailhwanpi extract in the present invention can be used to extract using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating brain cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against brain cancer used alone or used in the past.
  • the term "patient” refers to humans and horses, sheep, pigs, goats, camels, who have a disease caused by brain cancer and its direct and indirect causes, and whose symptoms can be improved by administering the composition of the present invention. Means antelope, dog and other animals.
  • a composition comprising the haphwanpi extract of the present invention, it is possible to effectively prevent and treat the above-mentioned brain cancer.
  • the composition of the present invention can be administered in parallel with existing brain cancer therapeutics.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to the sexually transmitted disease, age, severity, and drug activity of the patient.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.
  • the present invention also provides a cosmetic composition for preventing brain cancer containing Albizziae Cortex ethanol extract containing cosmetically acceptable cosmetic auxiliary additives as an active ingredient.
  • the cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the ethanol extract.
  • the cosmetic composition of the present invention is not particularly limited in the formulation, for example, it may have a flexible cosmetic water, nourishing cosmetics, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetic formulation, and also lotion, It may be a transdermal dosage form such as an ointment, gel, cream, patch or spray.
  • the present invention was completed by preparing a cosmetic composition for preventing brain cancer containing the haphwanpi extract as an active ingredient (see Preparation Example 2).
  • the haphwanpi extract of the present invention inhibits the growth of brain cancer cells and induces apoptosis. Therefore, the composition for treating brain cancer according to the present invention will be very effective in the treatment of brain cancer patients.
  • FIG. 1 is a result of the Alamar Blue analysis to determine the effect of the introduction of haphwanpi on the growth of brain cancer cells in human brain cancer U-87 MG cells.
  • the horizontal axis of the figure shows the concentration of the extract, the vertical axis shows the survival rate of brain cancer cells.
  • FIG. 2 is a result of Alamar Blue analysis to determine the effect of the introduction of turmeric extract on the growth of brain cancer cells in human brain cancer U-87 MG cells.
  • the horizontal axis of the figure shows the concentration of the extract, the vertical axis shows the survival rate of brain cancer cells.
  • haphwanpi Choinese
  • Seoul medicinal herb 3 kg was dried and ground for 5 days at the shade and room temperature.
  • the pulverized combined ring skin was immersed in 30 L of 95% ethanol and extracted at 50 ° C. for 24 hours. It was filtered through filter paper, dried and concentrated under reduced pressure at 45 ° C. to obtain 488 g of the total extract, which was stored at ⁇ 20 ° C.
  • Alamar Blue analysis was performed on U-87 MG, a human brain cancer cell.
  • the Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It is described in more detail below.
  • U-87 MG cells a brain cancer cell line used in the present invention, were distributed from the Korean Cell Line Bank (KCLB) and used for experiments.
  • MEM Minimum Essential Medium
  • FBS fetal bovine serum, fetal bovine serum
  • HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid
  • the Hwanhwanpi extract extracted in Example 1 confirmed the cell growth inhibitory effect on U-87 MG brain cells. Specifically, 8.0 x 10 per each well in a 96 well plate 3 The casualties were seeded in U-87 MG cells and dissolved in dimethyl sulfoxide (DMSO). When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1).
  • haphwanpi has a brain cancer treatment effect. Ie 2.3% at 3.125 ⁇ g / ml, 7.7% at 6.25 ⁇ g / ml, 8.6% at 12.5 ⁇ g / ml, 25.6% at 25 ⁇ g / ml, 61.5% at 50 ⁇ g / ml, 89.5% at 100 ⁇ g / ml Brain cancer cells were killed. In addition, the EC 50 (half maximal effective concentration) was determined to be 39.831 ⁇ g / ml.
  • Table 1 above describes the relative cell numbers of brain cancer cells after 48 hours according to the concentration of each monocyclic skin based on the number of survival rates of brain cancer cells of the control group not treated with monocyclic skin.
  • the Hwanhwanpi extract of the present invention has excellent U-87 MG cell killing activity, further demonstrating that it has a therapeutic and prophylactic activity for brain cancer.
  • the haphwanpi used in the present invention was widely used as a medicinal herb, so it was determined that there was no problem in stability, but the oral administration and the intraperitoneal administration were performed by conducting toxicological tests.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg, each of the Hwanhwanpi extract of Example 1 of the present invention suspended in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to observe abdominal and thoracic organ abnormalities.
  • Turmeric is a substance that shows anticancer activity against various kinds of cancers such as lung cancer, uterine cancer and breast cancer.
  • the inventors confirmed the effectiveness of the filamentous extract of the present invention by confirming the extent of the turmeric on the growth of brain cancer cells.
  • the turmeric extract was confirmed the growth inhibition of the U-87 MG cells in the same manner as in Example 2, and the results are shown in Table 2 and FIG.
  • turmeric hardly reduced the growth of brain cancer cells even when the treatment concentration was high.
  • turmeric widely known as an anticancer substance, has almost no brain cancer treatment efficacy, whereas the Hwanhwanpi extract of the present invention has excellent U-87 MG cell killing activity and further shows that it has brain cancer treatment and prophylactic activity.
  • the present inventors have confirmed that the brain cancer treatment effect of the haphwanpi extract through the above embodiment to prepare a brain cancer treatment containing the haphwanpi extract as an active ingredient as follows.
  • the preparation of the following therapeutic agent can be used for the application of the health food as well as the therapeutic agent.
  • Hwanhwanpi extract 35%, vitamin C 10%, vitamin D 3 0.001%, manganese sulfate 0.1%
  • the present inventors have confirmed that the haphwanpi extract has excellent brain cancer treatment activity through the above embodiment to prepare a cosmetic composition containing the same as an active ingredient as follows.
  • the nourishing cream was prepared by a conventional method according to the composition described below.
  • Glycerin 4.0%, Polyvinyl Alcohol 15.0%, Hyaluronic Acid Extract 5.0%, Beta Glucan 7.0%, Allantoin 0.1%, Hapkin Skin Extract 0.5%, Nonyl Phenyl Ether 0.4%, Polysorbate 60 1.2%, Ethanol 6.0%, Purified Water Residue
  • Ointments were prepared in a conventional manner according to the compositions described below.

Abstract

L'invention concerne une nouvelle utilisation d'un extrait d'Albizzia julibrissin et concerne notamment une composition pour prévenir et guérir le cancer du cerveau, la composition comprenant un extrait éthanolique d'Albizzia julibrissin en tant qu'ingrédient actif, et une composition cosmétique pour prévenir le cancer du cerveau, la composition cosmétique comprenant l'extrait éthanolique d'Albizzia julibrissin, qui comprend un additif de supplément cosmétique acceptable en cosmétologie en tant qu'ingrédient actif. La composition et la composition cosmétique pour traiter le cancer du cerveau selon la présente invention sont efficaces pour inhiber la croissance et provoquer la mort des cellules cancéreuses; cela permet de les utiliser efficacement pour prévenir et guérir le cancer du cerveau.
PCT/KR2012/001082 2011-02-11 2012-02-13 Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait d'albizzia julibrissin WO2012108748A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0012224 2011-02-11
KR1020110012224A KR101790738B1 (ko) 2011-02-11 2011-02-11 합환피 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물

Publications (2)

Publication Number Publication Date
WO2012108748A2 true WO2012108748A2 (fr) 2012-08-16
WO2012108748A3 WO2012108748A3 (fr) 2012-12-27

Family

ID=46639103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001082 WO2012108748A2 (fr) 2011-02-11 2012-02-13 Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait d'albizzia julibrissin

Country Status (2)

Country Link
KR (1) KR101790738B1 (fr)
WO (1) WO2012108748A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114656575A (zh) * 2022-03-07 2022-06-24 中国科学院上海药物研究所 一种合欢花非均一多糖，其制备方法及用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440237B2 (en) 2009-04-27 2013-05-14 Mary Kay Inc. Botanical anti-acne formulations
CA2859419C (fr) 2011-12-19 2018-10-16 Mary Kay Inc. Composition cosmetique refermant un extrait aqueux de petit haricot blanc
CN103006752B (zh) * 2012-11-19 2014-12-24 江苏大学 一种合欢皮抗肿瘤有效组分提取物及其制法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020080657A (ko) * 2001-04-17 2002-10-26 주식회사 참 존 합환피 추출물을 함유하는 항산화 화장료
KR100605115B1 (ko) * 2004-03-16 2006-07-28 주식회사 오스코텍 합환피 추출물을 유효성분으로 함유하는 면역억제제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020080657A (ko) * 2001-04-17 2002-10-26 주식회사 참 존 합환피 추출물을 함유하는 항산화 화장료
KR100605115B1 (ko) * 2004-03-16 2006-07-28 주식회사 오스코텍 합환피 추출물을 유효성분으로 함유하는 면역억제제

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, BYUNG DON ET AL.: 'Cytotoxicity of the Components of Albizziajulibrissin' THE JOURNAL OF APPLIED PHARMACOLOGY vol. 7, 1999, pages 371 - 376 *
KANG, BYUNG SOO ET AL.: 'Cytotoxic Activties and Antioxidative Activties Against Liver Cancer Cell of Albizzia root' THE JOURNAL OF APPLIED PHARMACOLOGY vol. 10, 2002, pages 371 - 376 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114656575A (zh) * 2022-03-07 2022-06-24 中国科学院上海药物研究所 一种合欢花非均一多糖，其制备方法及用途

Also Published As

Publication number Publication date
KR101790738B1 (ko) 2017-10-27
WO2012108748A3 (fr) 2012-12-27
KR20120092283A (ko) 2012-08-21

Similar Documents

Publication Publication Date Title
WO2012108749A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de graines de pharbitis
WO2012108748A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait d'albizzia julibrissin
WO2012108747A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de la racine d'helena
WO2012108746A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de racine de rubia cordifolia
WO2012108743A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait des graines de pharbitis blanc
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2015064899A1 (fr) Composition contenant, comme principe actif, un extrait mélangé d'aune japonais, de sagesse-des-chirurgiens et de peucedanum praeruptorum, ou une fraction associée pour prévenir ou traiter un cancer
WO2012108745A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de gleditsiae semen
WO2012099420A2 (fr) Composition et aliment fonctionnel comprenant des extraits d'élécampane et destinés au traitement du cancer du cerveau
WO2012108744A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de la fleur inula
WO2012099424A2 (fr) Composition et aliment naturel fonctionnel comprenant des extraits de fenugrec utilisés dans le traitement du cancer du cerveau
WO2012099419A2 (fr) Composition et aliment fonctionnel comprenant des extraits de cirsium japonicum et destinés au traitement du cancer du cerveau
WO2012108742A2 (fr) Composition et l'alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de fleur tussilago farfara
KR20120092269A (ko) 백화사설초 추출물을 포함하는 뇌암 치료용 조성물 및 건강 기능성 식품
WO2012099422A2 (fr) Composition et aliment naturel fonctionnel comprenant des extraits de lysimachiae foenum-graeci herba utilisés dans le traitement du cancer du cerveau
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120084121A (ko) 사상자 추출물을 포함하는 뇌암 치료용 조성물 및 건강 기능성 식품
KR20120092274A (ko) 애엽 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
WO2023055221A1 (fr) Composition comprenant un extrait d'avoine pour atténuer la chute des cheveux et favoriser la pousse des cheveux
KR101865374B1 (ko) 고량강 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
WO2012134251A2 (fr) Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120084120A (ko) 무이 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
WO2012134168A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum
KR20180027447A (ko) 대계근 추출물을 포함하는 뇌암 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12744362

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12744362

Country of ref document: EP

Kind code of ref document: A2